Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies
Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies
复制标题
DOI：
10.3390/jcm8091498
复制
发表时间：
2019-09-01
影响因子：
3.9
通讯作者：
Dicheva, Diana T.
中科院分区：
文献类型：
--
作者：
Andreev, Dmitrii N.;Maev, Igor, V;Dicheva, Diana T.
背景：幽门螺杆菌（H. pylori）的经典根除治疗方案的有效性出现了负面趋势，这在很大程度上是由抗生素耐药性的出现和蔓延决定的。多项研究表明，在根除方案中添加瑞巴派特可提高治疗效果。目的：评估瑞巴派特纳入幽门螺杆菌感染根除方案的有效性和安全性。方法：在 MEDLINE/PubMed、EMBASE、Cochrane Central Register、韩国医学引文索引和俄罗斯科学引文索引数据库中进行文献检索。所有确定的比较瑞巴派特补充剂与不含瑞巴派特根除方案治疗幽门螺杆菌感染的随机对照试验均纳入最终分析。结果：我们确定了 11 项随机对照试验 (RCT)，涉及 1227 名患者（使用瑞巴派特组中有 631 名患者，未使用瑞巴派特组中有 596 名患者）。荟萃分析显示，根除方案中添加瑞巴派特可显着提高治疗效果（比值比 (OR) 1.753，95% 置信区间 (CI) 1.312-2.333，p < 0.001）。亚组分析表明，瑞巴派特加入双重治疗方案后可显着提高根除效果（OR 1.766，95% CI：1.167-2.495，p = 0.006）；然而，当将其添加到三联疗法方案中时，没有观察到有效性的显着改善（OR 1.638，95% CI 0.833-3.219，p = 0.152）。结论：这项荟萃分析表明，在幽门螺杆菌根除方案中添加瑞巴派特可显着提高治疗效果。
Background: There has been a negative trend in the effectiveness of classic eradication therapy regimens for Helicobacter pylori (H. pylori), which has largely been determined from the emergence and spread of antibiotic resistance. Several studies have shown that adding rebamipide to eradication regimens leads to an increase in the effectiveness of treatment. Aim: To evaluate the efficacy and safety of including rebamipide in the eradication regimens for H. pylori infection. Methods: The literature search was conducted in the MEDLINE/PubMed, EMBASE, Cochrane Central Register, Korean Medical Citation Index, and Russian Science Citation Index databases. All identified randomized controlled trials comparing rebamipide supplementation with non-rebamipide-containing eradication regimens for the treatment of H. pylori infection were included in the final analysis. Results: We identified 11 randomized controlled trials (RCTs) involving 1227 patients (631 in groups with rebamipide and 596 in groups without rebamipide). The meta-analysis showed that the addition of rebamipide to eradication regimens significantly increased the effectiveness of treatment (odds ratio (OR) 1.753, 95% confidence interval (CI) 1.312-2.333, p < 0.001). The subgroup analysis demonstrated that rebamipide significantly increased the effectiveness of eradication when added to a dual therapy regimen (OR 1.766, 95% CI: 1.167-2.495, p = 0.006); however, no significant improvement in effectiveness was observed when it was added to the triple therapy regimen (OR 1.638, 95% CI 0.833-3.219, p = 0.152). Conclusion: This meta-analysis demonstrated that the addition of rebamipide to H. pylori eradication regimens significantly increases the effectiveness of treatment.